Loading clinical trials...
Loading clinical trials...
A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Conditions
Interventions
Nivolumab
Ipilimumab
+3 more
Locations
32
United States
Local Institution - 0037
New Haven, Connecticut, United States
Local Institution
Tampa, Florida, United States
Local Institution - 0031
Augusta, Georgia, United States
Local Institution - 0006
Chicago, Illinois, United States
Local Institution - 0007
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
February 2, 2017
Primary Completion Date
November 23, 2021
Completion Date
November 23, 2021
Last Updated
December 19, 2022
NCT04657068
NCT04900818
NCT05004116
NCT06440005
NCT07246954
NCT06242470
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions